Tag Archives: Market

Global Bipolar Disorders Market to Reach $5.7 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

August 03, 2012     No comments

San Jose, California (Vocus) June 11, 2010

Bipolar disorder is a chronic and devastating psychiatric disease. Since neither curable nor effectively treatable, the bipolar disorder market is present with significant unmet medical needs. The major drawbacks of existing products include dyskinesis, obsessive-compulsive behavior and psychiatric side effects, as well as ineffectiveness in treating cognitive deficits, rapid recycling or depressive symptoms. In addition, though anti-convulsants (such as Valproic acid) and lithium have considerably enhanced disease prognosis, several patients show poor tolerance to treatment-related side effects. Other major clinical setbacks include lack of compliance to treatment regimen, inadequate clinical response, and relapse.

The United States dominates the world bipolar disorder market as stated by the new market research report on bipolar disorder market. According to the U.S. National Institute of Mental Health, there are about 5.7 million adults aged 18 years and over, suffering from bipolar disorder in the US. The treatment of bipolar disorder differs based on physician specialty in the country. Most psychiatrists follow the recommendations of the American Psychological Association and prescribe lithium, valproic acid and atypical antipsychotics as first-line monotherapies for bipolar mania, and Lamictal as the recommended treatment for bipolar depression. And, unlike the psychiatrists who follow the APA guidelines and prescribe Lamictal first-line, primary care physicians select antidepressants first line.

Bipolar disorder is highly consolidated marketplace with the leading five players accounting for the lion?s share of the market. These players are unlikely to face any major challenge(s) in the future, as pipeline molecules are all targeted at providing only symptomatic relief, and no company is developing any therapy that promises a paradigm shift in the treatment of bipolar disorder. Key players profiled in the report include Abbott Laboratories Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Cephalon Inc., Dainippon Sumitomo Pharma Co. Ltd., Eli Lilly and Company, Forest Laboratories Inc., Gedeon Richter PLC, GlaxoSmithKline PLC, H. Lundbeck A/S, Janssen Pharmaceutica Inc., Merck & Co., Inc., Otsuka America Pharmaceutical Inc., Pfizer Inc., Repligen Corporation, and Validus Pharmaceuticals Inc.

The report titled ?Bipolar Disorders: A Global Strategic Business Report? announced by Global Industry Analysts Inc., provides a review of unmet medical needs, opportunities and challenges, patent expiries, competitive scenario, select leading products, select pipeline drugs, clinical trials, product approvals/launches, recent industry activity, and coverage on major global market participants. The study analyzes market data and analytics in terms of value sales for regions including The United States, Europe, Asia-Pacific and Rest of World. Global market is analyzed by the following drug classes – Atypical Anti-psychotics and Other Therapeutics.

For more details about this market research report, please visit ?

http://www.strategyr.com/Bipolar_Disorders_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world?s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone 408-528-9966

Fax 408-528-9977

Email press(at)StrategyR(dot)com

Web Site http://www.StrategyR.com/

###







Read More

Beer Wholesaling in the US Industry Market Research Report Now Available from IBISWorld

July 27, 2012     No comments


Los Angeles, CA (PRWEB) July 09, 2012

While other wholesalers face the threat of bypass or competition from suppliers that vertically integrate, three-tier distribution laws that require separation between manufacturers and retailers insulate beer distributors. After Prohibition, most states implemented laws that require three distinct levels within the supply chain: producer, wholesaler and retailer. As a result, beer wholesalers have a protected role, and their revenue remains relatively stable through good times and bad, according to IBISWorld industry analyst Agata Kaczanowska. As a middleman serving the Breweries industry (IBISWorld report 31212), the Beer Wholesaling industry is in the mature stage of its life cycle, with a relatively steady profit of about 16.1%.

Role security does not mean that the Beer Wholesaling industry has conducted business as usual since 2007. Changing tides from upstream and downstream industries have reshaped the wholesaling landscape, Kaczanowska says. Beer production has changed rapidly, with more than four-fifths of its market share consolidated into just two companies (AB InBev and MillerCoors), and craft brewery popularity is growing. Meanwhile, changing consumer preferences have created other difficulties for wholesalers. Average consumption stagnated as Americans flocked to wines and cocktails during times of prosperity and shifted spending to cheaper brands during the recession. A recovery in 2012 is expected to stimulate a 0.3% revenue increase, and a combination of the above factors has caused revenue to decline at an average annual rate of 0.5% to $ 57.8 billion over the five years to 2012.

Slowly increasing consumer spending will help the Beer Wholesaling industry’s revenue to gain some momentum during the next five years. IBISWorld projects that revenue will grow during the five years to 2017. Once consumer spending rebounds, prices are expected to increase, facilitating revenue growth. Meanwhile, volumes will remain stagnant as strong demand for regional or microbrews cuts into mainstream sales. Revenue growth and a decline in firm numbers means that surviving firms will be larger and average company earnings will increase. Despite consolidation in this industry, the average industry profit margin is expected to stay steady as producers and retailers continue to squeeze the middleman’s margins. For more information, visit IBISWorld?s Beer Wholesaling in the US industry report page.

Follow IBISWorld on Twitter: https://twitter.com/#!/IBISWorld

Friend IBISWorld on Facebook: http://www.facebook.com/pages/IBISWorld/121347533189

IBISWorld industry Report Key Topics

This industry comprises establishments primarily engaged in purchasing, storing, selling and distributing beer and other fermented malt beverages that are made by the Breweries industry (IBISWorld report 31212).

Industry Performance

Executive Summary

Key External Drivers

Current Performance

Industry Outlook

Industry Life Cycle

Products & Markets

Supply Chain

Products & Services

Major Markets

Globalization & Trade

Business Locations

Competitive Landscape

Market Share Concentration

Key Success Factors

Cost Structure Benchmarks

Barriers to Entry

Major Companies

Operating Conditions

Capital Intensity

Key Statistics

Industry Data

Annual Change

Key Ratios

About IBISWorld Inc.

Recognized as the nation?s most trusted independent source of industry and market research, IBISWorld offers a comprehensive database of unique information and analysis on every US industry. With an extensive online portfolio, valued for its depth and scope, the company equips clients with the insight necessary to make better business decisions. Headquartered in Los Angeles, IBISWorld serves a range of business, professional service and government organizations through more than 10 locations worldwide. For more information, visit http://www.ibisworld.com or call 1-800-330-3772.







Related Alcoholism Press Releases

Read More

Global Irritable Bowel Syndrome (IBS) Therapeutics Market to Reach $1.47 Billion by 2017, According to a New Report by Global Industry Analysts, Inc.

July 24, 2012     No comments

(PRWEB) August 25, 2011

San Jose, California (PRWEB), August 25, 2011 — Irritable Bowel Syndrome, a recurring Gastrointestinal illness, represents an under-penetrated market with a large number of generic drugs presently in use for treating the multiple symptoms. Owing to lack of proper understanding of the disease etiology, the causes, and misdiagnosis of symptoms, only countable number of drugs is presently available in the market for treating more than one symptom associated with IBS. However, over the years, the market has witnessed several improvements, such as the establishment of well-defined diagnostic criteria, exploring novel therapeutic drug classes, emergence of alternative medicines and therapies, in addition to the growing awareness about the chronic nature of the disease.

The global market for Irritable Bowel Syndrome (IBS) therapeutics is presently underserved with a high degree of fragmentation due to the non-availability of a single drug for treating all symptoms associated with this chronic illness. Further, upon considering the diagnostic scenario, nearly 70% of the cases remain undiagnosed while the disease prevalence is quite high. During the initial onset of the disease, patients prefer self-medication based upon their symptoms and rely upon OTC products. The prescription market for IBS comprises of a very few approved drugs for addressing more than one symptom, which show only sub optimal efficacy, and in some cases result in adverse side effects. Physicians prescribe multiple drugs that are not adequate for subsiding the pain, discomfort, and other IBS symptoms. The approval and subsequent release of safe and effective medicines for IBS treatment in the near future is expected to result in substantial growth of the IBS market owing to the premium pricing of these drugs upon release.

The US represents the largest market for irritable bowel syndrome (IBS) therapeutics worldwide, as stated by the new market research report on Irritable Bowel Syndrome Therapeutics. Europe represents the second largest market for IBS therapeutics. Rest of World is projected to emerge as the fastest growing market for IBS therapeutics, exhibiting a CAGR of more than 12% over the analysis period.

The high prevalence and anticipated launch of new drugs in the developed markets during and post 2012 is expected to drive the growth of the IBS market in the coming years. Lotronex (2000) and Amitiza (2008) are the only drugs presently approved for the treatment of Diarrhea Predominant IBS (IBS-D) and Constipation Predominant IBS (IBS-C), respectively. Post US FDA approval and market release in February 2000, Lotronex was withdrawn from the US market in December 2000 owing to safety concerns over this drug. Lotronex was re-launched in 2005, although with a warning label, for restricted use in patients in whom the risk to benefit ratio is balanced. The re-launch of the drug despite the risk associated with its use reflects the high unmet need existing in the IBS therapeutics market. Amitiza, approved for the treatment of IBS-C, is associated with adverse events and side effects. The drug?s safety profile limits the drug?s market size despite its efficacy.

The late stage drug pipeline of Irritable Bowel Syndrome comprises of drug candidates with novel mechanisms of action, and do not belong to the 5HT class of drugs which dominated the drug-development pipeline for the past several years. Despite the efficacy, 5HT class of drugs lack gut-selectivity acting on receptors present in the gut as well as the brain, which is the primary reason for the side effects associated with their use. New drugs in the late stage IBS pipeline, including Linaclotide, Asimadoline, and Dexloxiglumide, exhibit novel modes of action and have demonstrated positive results in terms of safety and efficacy in their respective late stage clinical trials, which makes them promising candidates in the field of IBS treatment. Moreover, each of these is found to be effective in treating a particular IBS-subtype, and not just a single symptom associated with IBS, in respective clinical studies.

Major players profiled in the report include Abbott Laboratories, Edusa Pharmaceuticals, Ironwood Pharmaceuticals Inc., Forest Laboratories Inc., Lexicon Pharmaceuticals, Ocera Therapeutics Inc., Pharmos Corporation, Sucampo Pharmaceuticals Inc., Tioga Pharmaceuticals Inc., among others.

The research report titled ?Irritable Bowel Syndrome (IBS) Therapeutics: A Global Strategic Business Report? announced by Global Industry Analysts Inc., provides a comprehensive review of the Irritable Bowel Syndrome (IBS) market, the disease prevalence, classification, causes, diagnosis, current treatment scenario, select treatments and therapies along with side effects, product approvals in the past, clinical trials, early and late stage pipeline, recent industry activity, product innovations, and profiles of major/niche global market participants. The report provides annual value sales estimates and projections for Irritable Bowel Syndrome Therapeutics market for the years 2009 through 2017 for the following geographic regions ? US, Japan, Europe, and Rest of World. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.

For more details about this comprehensive market research report, please visit ? http://www.strategyr.com/Irritable_Bowel_Syndrome_IBS_Therapeutics_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world’s largest and reputed market research firms.

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

Email: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/

###







More Early Onset Press Releases

Read More

Global ADME-Toxicology Testing Market to Exceed $10 Billion by 2017, According to a New Report by Global Industry Analysts, Inc.

July 21, 2012     No comments

San Jose, California (PRWEB) August 29, 2011

New drug discovery is increasingly becoming a high cost proposition for pharmaceutical and biotech companies, owing particularly to the high attrition rate due to drug failure at different stages. Development of a new drug costs about $ 1.0 billion and takes, on an average, 7-10 years before reaching commercialization stage. With companies facing major revenue losses owing to patent expirations and demanding regulatory requirements, besides growing cost pressures, there is growing need to reduce fixed costs and adopt flexible cost models. ADME-Tox issues comprise a leading cause for drug failure/attrition during the pre-clinical as well as clinical stage. The increasing number of drug targets and volume of assay points in drug discovery process are necessitating the need for identifying and eliminating potential hits with high ADME and toxicity profiles. Hence ADME/Tox screening has now become essential at early stage drug discovery and development process. In addition, rising drug discovery costs are fostering the adoption of extensive ADME-Tox screenings not only at early stage of drug discovery and development process but also through the entire process.

Pharma companies are focusing efforts on various innovative approaches to enhance and accelerate ADME-Tox assessments. In silico predictive ADME-Tox is growing at a fast clip and is expected to gain further momentum as the technology can drastically reduce the expenditure incurred due to late stage failure of drug compounds owing to poor ADME-Tox properties. The use of computational models in prediction of ADME/Toxicity properties of compounds is also increasing at a rapid rate owing to the fact that these models offer significant benefits in high throughput screening (HTS). Owing to the significant role of transporter proteins, analysis of drug transporters is gradually becoming a part of ADME assessment and is likely to become a part of regulatory standard for new drug applications.

The United States and Europe account for a lion?s share of the global ADME-Toxicology testing market, as stated by the new market research report on ADME-Toxicology Testing. With the US being home to most of the global pharmaceutical giants, the nation corners a major share of new drug discoveries across the world. The US market for In-Vivo Toxicology testing is forecast to exceed US$ 1.0 billion by 2015. Cell-based assays are expected to emerge as a vital technology in in-vitro test methods in toxicity testing, given their role either as a part of a tiered testing scheme or as test batteries in predicting human toxicity endpoints. Growing interest in screening new drug candidates has propelled the manufacturers of cell-based assays to provide reliable and robust solutions for drug discovery. High Throughput/High Content (HTS/HCS) cell-based assays enable the evaluation of several toxicity endpoints, which is expected to enable identification of various aspects associated with the onset of cell stress. This, in turn, aids in predicting specific cytotoxic effects.

While the US is expected to continue its dominant position in global market, developing regions including Asia-Pacific are poised to register the fastest growth. The high growth in these markets is buoyed by government support and increasing number of collaborations between foreign pharma companies and research laboratories in the region. In particular, India and China have rapidly emerged as ?hot spot? for R&D investment. The emergence and success of contract research organizations (CROs) has made outsourcing of various research projects related to new drug development a viable alternative for pharmaceutical companies, particularly for mid-tier and small players with inadequate infrastructure. Increasing emphasis on early stage ADME-Tox screening and prediction during the last decade and a half has resulted in emergence of large number of dedicated ADME-Tox CROs.

ADME-Tox technologies market place includes pharmaceutical and biotech companies with their in-house research teams and contract research organizations (CROs) that provide ADME-Tox screening at contract. Select players profiled in the report include Accelrys, Inc., ACEA Biosciences, Inc., Agilent Technologies, Inc., Albany Molecular Research, Inc., BD Biosciences, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Caliper Life Sciences, Inc., Cambridge Cell Networks Ltd, CeeTox, Inc., Cellartis AB, Celsis International Ltd., Cyprotex PLC, Entelos, Inc., Life Technologies Corporation, Molecular Discovery Ltd., MultiCASE, Inc., Noray Bioinformatics S.L., Optivia Biotechnology, Inc., Promega Corporation, Taconic Farms, Inc., Thermo Fisher Scientific, Inc., Xceleron, Inc. among others.

The research report titled ?ADME-Toxicology Testing: A Global Strategic Business Report? announced by Global Industry Analysts Inc., provides a strategic review of the drug discovery and development market, key market trends in ADME-Tox Technologies, recent product launches, strategic corporate initiatives, and profiles of key market participants. The report provides annual expenditure on ADME-Tox Technologies by the following geographic markets – US, Canada, Japan, Europe and Rest of World. Segments analyzed include Toxicology (In-Vivo and In-Vitro) and ADME.

For more details about this comprehensive market research report, please visit ? http://www.strategyr.com/ADME_Toxicology_Testing_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world’s largest and reputed market research firms.

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

Email: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/

###







Read More

LeadConfirm Professional, the first oral based lead test, makes getting the lead out easier. ”Aimed for the professional market, LeadConfirm Professional is less invasi

July 17, 2012     No comments


San Diego (Vocus) July 1, 2009 ?

Until now, determining a person?s lead exposure has been an invasive procedure involving painful blood tests.

However, that has changed thanks to LeadConfirm Professional, a new saliva-based test that screens for lead exposure in the body using oral fluids. The product is now available in the UK at selected distributors.

Developed by Confirm BioSciences, a San Diego-based biotech company, this test does not require any needle sticks or blood from the body. Just a few simple swabs of the inside cheek is all that is needed to determine how much lead a person has been exposed to.

LeadConfirm Professional comes at just the right time. According to the Occupational Safety and Health Administration, more than 1 million workers in more than 100 different occupations are exposed to lead every day, making lead overexposure one of the most common overexposures found in industry, and one of the leading causes of workplace illness.

Even worse: OSHA also notes that lead is also a major potential public health risk; one that may be present in hazardous concentrations in food, water, and air and sources include paint, urban dust, and folk remedies.

Lead poisoning is the leading environmentally induced illness in children and nearly 1 million children five years and younger have lead levels equal or greater to the levels experts consider ?dangerous.?

The effects of lead poison on children include speech delay, hyperactivity, attention deficit disorder, behavioral disorders, learning disabilities, stunted growth, neurological and renal damage, mental retardation, anemia, and hearing loss

“There is tremendous need for this product, as lead poisoning is a major issue in our society,? said Zeynep Ilgaz, President and Founder of Confirm BioSciences and a mother of two small children. ?We are seeing an increase in consumers wanting to better manage their own health care and Confirm BioSciences is responding to that growing market by developing new platform technologies that help to improve the health and wellness of children and individuals,” she continued.

“LeadConfirm is an indispensable tool to detect heavy metal pollutants that is so prevalent in consumer products. We are very proud to introduce this product to the UK and feel that this will benefit any concerned employer, parent or adult seeking a healthier work or living environment.” Said Chester Ku-Lea, CEO of Astro Supplements, one of the first distributors in the UK.

Unlike existing tests which use invasive blood tests, LeadConfirm Professional screens for lead exposure in the body using saliva, a vital bodily fluid that carries molecules, many bio markers of disease, evidence of drug use and many other indicators (known and unknown) of what is happening inside the human body.

In addition, existing tests are usually only performed after a healthcare professional suspects lead exposure ? and often that is too late for anything to be done. However, the non-invasive nature of LeadConfirm Professional makes it easier to check for lead exposure ? and, if needed, prescribe treatment ? sooner than ever.

Researchers analyzed the saliva of 100 children living in North Carolina at the same time as those childrens? blood was by that state?s Department of Health. Studies determined a 1.00 (100%) correlation between lead levels found in the saliva tests vs. blood tests making lead test as accurate as a blood test.

By comparing the results of the two lead test studies it became apparent that analyzing saliva is an effective means to establish body lead ? especially if this test is viewed as a ?screening method? with the recommendation of a physician involved in the event results exceed a certain level.

LeadConfirm Professional comes with a FDA approved collection device that should be administered by a doctor or healthcare professional. Once the saliva is collected, the vials are sent to the lab with a pre-paid envelope provided in the kit and the results can be accessed online or by phone within 5-6 business days after the lab receives the kit.

The tests are analyzed CLIA by state-of-the-art Liquid Chromatography (HPLC) with Mass Spectrometry X2 (LC/MS/MS) technology to determine the amount of lead present in the body. Positive results should be followed up with a physician for further analysis and treatment.

Confirm BioSciences has successfully developed and manufactured numerous screening tests including HairConfirm, the first at home hair follicle drug test in the market, and SteroidConfirm the first steroid test kit on the market.

In addition, Confirm BioSciences distributes products in over 50 countries throughout the world under brand-name or private-label arrangements.

LeadConfirm Professional is currently available in the UK at Astrosupplements (http://astrosupplements.com/) . The Product retails for $ 79.99 (includes lab fee and prepaid envelope to the lab).

About Confirm BioSciences

Confirm BioSciences is a provider of diagnostic drugs of abuse and health test kits. The company is privately held and based in San Diego. For more information, visit http://www.confirmbiosciences.com.

? 2009 by Confirm BioSciences, Inc. All rights reserved.

###







Read More

Us Navy Band Cruisers Welcomed To St. Charles Friday Night For Free Concert; Farmers Market, Local Artists, Romano Vineyard and Winery, Chick-fil-A? Join Cruisers for a Complete Night of Food and Entertainment

July 16, 2012     No comments

St. Charles, MD (PRWEB) June 28, 2012

The St. Charles Companies this week welcomes the U.S. Navy Band Cruisers to the St. Charles free waterfront Sunset Concert Festival this Friday, June 29th at 7 p.m. As the U.S. Navy’s premier contemporary entertainment ensemble, the Cruisers feature eight of the Navy’s most dynamic performers. Formed in 1999 as a specialty unit of the United States Navy Band, the Cruisers takes its name from the Navy’s versatile, flexible, multi-missioned ship ? the Cruiser ? and the band lives up to its namesake by having the capabilities of playing genres of music ranging from jazz & standards, rhythm & blues, classic rock, adult contemporary and pop as well as original material. This elite group has engaged and excited audiences of all ages throughout the U.S. and abroad with world-class musicianship and high energy, fun-filled performances. For more information, visit the Band?s website at http://www.navyband.navy.mil/cruisers.shtml.

Along with the concert, residents and visitors from Waldorf and Southern Maryland can enjoy the St. Charles Farmers Market from 4-7:30 p.m. on Friday with delicious produce, fresh flowers, desserts, baked goods, honey and hand-crafted soaps and can dine on chicken sandwiches, salads, wraps, sides and drinks from Chick-fil-A?. The last Friday of each month is Local Artists Night, and several local artists will be on hand with beautiful handmade original art and craft products courtesy of Southern Maryland Arts and Culture (http://www.somdarts.com).

Joining the Cruisers, artists and Farmers Market on the waterfront venue once again will be Romano Vineyard and Winery, a Maryland-bred and family-run vineyard to the Farmers Market and Summer Concert venue. The vineyard is home to six wine grape varietals ? Cabernet Franc, Merlot, Chambourcin, Vidal, Cayuga and Traminette ? as well as six table grape varietals and only produces wines from the grapes grown in their vineyard and those of carefully selected custom growers. Quality over quantity is the hallmark of Romano wines. (Proof of age required to purchase wine and wine cannot be opened in the O?Donnell Lake Restaurant Park venue.)

This week is also local wine and cheese week. Romano Winery will be joined by the P. A. Bowen farmstead, a Brandywine, Maryland farm that produces two signature artisan cheeses, Prince George?s Blue and Chesapeake Cheddar, available for sale during the concert while supplies last.

The Sunset Concert Festival is a summer-long arts festival sponsored by The St. Charles Companies and the Southern Maryland Agricultural Development Commission. Featuring a variety of local artists and musical genres, the concerts are being held every Friday night beginning at 7 p.m.

For more information, visit us on Facebook at stcharlesmd. Bands perform in the promenade area of the boardwalk, which is in the center of the property. Plenty of free parking is available and concert goers are encouraged to bring blankets or chairs for seating. Coolers are permitted, but alcohol and glass containers are not permitted. Concerts will end at dusk and all performances are free and open to the public. The O?Donnell Lake Restaurant Park is located at the intersection of St. Patrick?s Drive and Smallwood Drive West in St. Charles, across from the movie theater and the St. Charles Towne Center. Directions: From Route 301, turn onto Smallwood Drive West. Go through two lights, and O?Donnell Lake will be on your right, just past Sears Automotive. For directions using internet-based map programs, use the address 10440 O?Donnell Place.

Featured in 2011 in the Washington Post?s ?Where We Live? section, St. Charles is the largest population center in Charles County and is known for its diverse and abundant neighborhoods, lively retail centers, recreational opportunities and excellent schools. St. Charles is marketing exciting new single family homes from the $ 280?s and townhomes from the $ 190?s available from homebuilders Lennar, Ryan Homes and Richmond American. St. Charles recently announced the completion of The Nines at Gleneagles, the second phase of three new apartment communities in the Gleneagles neighborhood. The Company plans to begin construction of the third apartment community, which includes an additional 213 units, in early 2013. St. Charles appeals to all ages and lifestyles and was recently named by U.S. News and World Report as one of the nation?s top bargains for places to retire.

The St. Charles Companies (http://www.stcharlesmd.com) includes American Community Properties Trust, The Apartments of St. Charles, American Land Development and St. Charles Community, LLC. The St. Charles Companies? lines of business include the residential and commercial development of St. Charles, a 9,100 acre planned community in Charles County, Maryland and the ownership of an operating apartment portfolio of approximately 2,500 units in St. Charles.







Read More

Rising Incidence and High Relapse Rates Drive the Global Acute Myeloid Leukemia (AML) Therapeutics Market, According to New Report by Global Industry Analysts, Inc.

July 12, 2012     No comments

San Jose, CA (PRWEB) July 06, 2012

Follow us on LinkedIn ? Acute Myeloid Leukemia (AML) is identified as a rapidly progressing disease, associated with the elderly. Presently, approved drugs available for the treatment of AML include chemotherapy drugs such as cytarabine, anthracycline, daunorubicin, and mitoxantrone. These therapies, however, are marred with various negative factors such as low cure rates, major side effects such as neutropenia, and high relapse rates. Although other treatment options, such as bone marrow transplant offers comparatively better result, it is however not an effective option for most of the elderly patients due to its high toxicity and dearth of appropriate donors for the procedure. Therefore, the AML market is presently characterized by high unmet needs in terms of drug safety and efficacy presenting increased opportunities for new drugs with improved safety and efficacy profiles.

Over the years, the acute myeloid leukemia (AML) market has witnessed promising targeted drugs failing clinical trials, leading to the slowing down of growth prospects in the AML therapeutics scenario. Some of the promising targeted agents which have failed to improve outcomes in clinical trials include zosuquidar (P-glycoprotein modulator), sulfonylhydrazine alkylator laromustine, and Mylotarg (gemtuzumab ozogamicin). However, innovative new target agents are under various stages of clinical trials, which are expected to showcase promising results in the years to come. Also, AML therapeutic market, in recent years, has witnessed a surge in research and development activities centered on developing molecular targets, which target cell death (apoptosis) and cell cycling, apart from developing novel agents, which target DNA replication and repair. Other approaches which are being developed include immunotherapy and epigenetic based targeting. However, some of these approaches are still in their nascent stages of development, while others are exhibiting promising outcomes. In the upcoming years, the outcome of AML therapeutics are expected to be geared towards developing treatments which are less toxic and potentially safe for the elderly population, when compared to the traditional drugs.

One of the major drivers for the global AML market is the aging population worldwide. Since the incidence of AML significantly increases in the age group of 50 years and above, the aging population therefore forms a major portion of the population seeking treatment for AML. Strong growth for AML therapeutics emanates from developed regions, which have higher percentage of population in the 65+ age group, when compared to the developing countries. Developed markets, such as Europe, the US, and Japan, therefore account for a significant portion of the AML therapeutics market, when compared to the developing economies. While the present treatment of AML for elderly patients remain unimpressive, future strategies adopted by drug developers however are geared towards developing novel target based agents.

As stated by the new market research report on Acute Myeloid Leukemia Therapeutics, the US represents the largest and the fastest growing regional market worldwide. After the US, Europe forms the second largest market for AML therapeutics. Vidaza from Celgene Corp., and Ceplene from Epicept are the major AML drugs in Europe.

Given the fact that leukemia is a relatively smaller market (accounting for a meager 1% of the total cancer cases), and the development of drug in this area proving to be less lucrative for developers, there has been a dearth of investments in AML market over the years. However, various regulatory authorities such as the US FDA and European Medicines Agency (EMA) have taken up initiatives to incite interest among pharmaceutical companies to develop innovative therapies targeting AML. One such initiative taken by the regulators is awarding of orphan drug status and fast track designations or both for drugs that are being developed for AML. The move is expected to provide the much needed impetus to the market, as developers can reap benefits on investment faster, with drug hitting the markets at a faster pace and also gaining from the exclusivity benefit of the drug for a longer time period. Furthermore, with high relapse rates, the goal of treatment for AML is centered upon developing therapies, which aid in prolonged remission. Also, Stem cell transplantation, which hitherto has limited therapeutic application in AML market, are expected to become much more refined, thereby improving the scope of stem cell transplantation, particularly for use in low-intensity procedure for the elderly.

Major players in the market include Ambit Biosciences Inc., Aprea AB, Astellas Pharma Inc., Astex Pharmaceuticals Inc., Bio-Path Holdings Inc., BioSante Pharmaceuticals Inc., Celator Pharmaceuticals Inc., Celgene Corp., Clavis Pharma ASA, Cyclacel Pharmaceuticals Inc., EpiCept Corp., Genzyme Corp., Lorus Therapeutics Inc., Novartis AG, Onconova Therapeutics Inc., Sunesis Pharmaceuticals Inc., among others.

The research report titled ?Acute Myeloid Leukemia (AML) Therapeutics: A Global Strategic Business Report? announced by Global Industry Analysts Inc., provides a comprehensive review of the AML market, the present treatment options, molecular profile of presently approved drugs, the unmet medical needs, key growth drivers, market challenges, pipeline analysis including late-stage drug pipeline, recent FDA and EMAE approvals, drugs obtaining fast track and orphan drug designations, failed drugs, clinical trials, mergers and acquisitions, other strategic corporate deals, and profiles of major and niche key players globally and across different regions. The report provides annual sales estimates and projections for AML Therapeutics market in US$ Million for the years 2009 through 2017 for the following geographic markets – US, Japan, Europe, and Rest of World.

For more details about this comprehensive market research report, please visit ?

http://www.strategyr.com/Acute_Myeloid_Leukemia_AML_Therapeutics_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world’s largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

Email: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/







Read More

New Flying Sports Disc To Hit The Market In Time For The Holiday Toys Craze

July 09, 2012     No comments


Charlotte, NC (PRWEB) July 06, 2012

A colorful new sports disc known as the LunaDisc will soon light up the night sky, in time for the holidays.

The LunaDisc is a 100% cotton, crocheted colorful flying disc that has LED lights. Like the original Pocket Disc, the LunaDisc will be safe for play both indoors and outdoors and is fun for kids and adults.

Currently, the LunaDisc is available for pre-order on the popular crowdfunding website Kickstarter.

Products Are Popular With Disc Golf And Outdoor Enthusiasts

The Pocket Disc, made by Phd Productions, is already a hit with disc golfers, and the LunaDisc will allow them to play into the night.

Interest in disc golf sports has grown exponentially in the past couple years. According to the Professional Disc Golf Association (PDGA), the number of registered PDGA players has risen to over 16,000, with hundreds of thousands of others playing casually.The prize purses at disc golf tournaments have grown to a total of over $ 2 million.

This year?s Disc Golf Pro-Am World Championship will be in Charlotte. This will be Charlotte?s third time hosting the tournament and the first time since 1997.The tournament will be split up by divisions, with 25 divisions competing this year, and will be played at 14 different courses. Phd Productions will be at the event to promote the Pocket Disc and LunaDisc.

LunaDisc Will Add A Fun Dimension To Flying Disc Games

Phd Productions also sells to many others who enjoy indoor and outdoor flying disc games.

The company has created a popular game, iGolf, that takes disc golf and customizes it for indoor play. There are also many variations of the game, and players are encouraged to develop their own style of play. There are many other games listed on their website: http://www.pocketdisc.com/games.php

?We?re excited to expand our market with the new LunaDisc,? said Phd Productions Co-Founder Patrick Groft. ?We think it will be a fun, hot toy this holiday season and a great gift for kids of all ages.?

The last day to pre-order the LunaDisc on Kickstarter is August 5.

About Phd Productions

Phd Productions, LLC, the creator of the Pocket Disc, is based in North Carolina. Pocket Discs can be purchased at a variety of retailers nationwide including LL Bean, Eastern Mountain Sports, Learning Express Toys, many independent Play-It-Again Sports and over 1,500 specialty toy, gift and outdoor retailers. For more information and a store locator visit http://www.pocketdisc.com.







Read More

Global Anxiety Disorders Market to Reach $5.9 Billion by 2017, According to a New Report by Global Industry Analysts, Inc.

July 08, 2012     No comments

San Jose, CA (Vocus/PRWEB) April 12, 2011

GIA announces the release of a comprehensive global report on Anxiety Disorders market. The global market for anxiety disorders is forecast to reach $ 5.9 billion by the year 2017. Key factors driving market growth include rising stress levels that are further augmented by the recent financial crisis, increasing incidence and prevalence of anxiety disorders, growing aging population globally, existence of significant unmet needs, and the development of novel therapeutics.

Stress is one of the most significant health issues of the twenty-first century, to the extent of being called a global epidemic. Anxiety is a normal reaction to stress, which helps one deal with tense situations in the office, study harder for an exam, or keep focus on an important speech. In general, it helps one cope. But when anxiety becomes an excessive, irrational dread of everyday situations, it turns into a disabling disorder. Anxiety disorders represent the most commonly occurring mental health condition, affecting individuals of all age groups. In the recent years, the number of people suffering from anxiety disorders increased considerably owing to the global financial crisis that resulted in rising unemployment rates, and increasing stress levels. Ever-increasing aging global population is also one of the factors responsible for the rapid increase in sales of central nervous system drugs. Major types of anxiety disorders with high prevalence include Social Anxiety Disorder, Post-Traumatic Stress Disorder, Generalized Anxiety Disorder, Panic Disorder, and Obsessive-Compulsive Disorder.

Anxiety therapy addresses and eliminates specific factors causing the disorder and inhibits their reoccurrence, thereby helping in restoring and maintaining normal health of the affected individuals. The first line of agents used for the treatment of anxiety includes Selective Serotonin Reuptake Inhibitors such as Lexapro (Escitalopram), Paxil (Paroxetine), Zoloft (Sertraline), and Prozac (Fluoxetine). The other medications prescribed consist of GABA analogues, including new antidepressant Remeron (Mirtazapine); and MAOIs including Parnate (Tranylcypromine) or Nardil (Phenelzine), Lyrica (Pregabalin) or Neurontin (Gabapentin). TCAs, including Imipramine; atypical anti-psychotics including Quetiapine; and Piperazines including hydroxyzine, are also used for the treatment of anxiety. However, these medications are known to cause various side effects and complications.

Despite being the foundation for pharmacological treatment pertaining to anxiety disorders, the response rate of serotonergic-based treatment is more often below the robust level. In addition, though an array of treatment options are available for treating anxiety disorders, about one-third of patients suffering from psychiatric conditions still do not respond to the drugs that are presently available in the market. There exists an ever-increasing need for developing medications that offer a faster onset of action as compared to the presently available drugs. The research projects being undertaken by companies partly focus on the conventional mode of action, such as adjustment of nor-adrenaline and serotonin levels in the brain, and partly on unique and new mechanism. Physicians are looking at novel drugs for the treatment of anxiety disorders.

The existence of Neurokinin (NK) receptor antagonists, along with Corticotrophin Releasing Factor (CRF) antagonists within the anxiety disorders pipeline, drew major interest from key market participants. The NK receptor antagonists are expected to emerge as promising drugs for the treatment of anxiety disorders. Further, the market is expected to witness a transformation, with anti-psychotic drugs expected to change the future landscape of the anxiety disorder drugs market. Manufacturers of antidepressants are expected to enhance their products’ target patient potential, considering the higher co-morbidity between depression and anxiety.

The US represents the largest regional market for anxiety disorder therapeutics worldwide, as stated by the new market research report on Anxiety Disorders. The US registers the highest number of anxiety disorder cases annually. The country incurs a cost of over US$ 42 million per annum for anxiety disorders, which accounts for almost one-third of the overall cost for mental illnesses. About 27% of the European population suffers from brain disorders, with depression being the most prevalent health problem in several EU-Member States. However, Asia-Pacific is forecast to register the fastest growth during the analysis period, registering a compounded annual growth rate of more than 5.0% during 2009-2017.

Major players profiled in the report include AstraZeneca Plc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Forest Laboratories, Inc., GlaxoSmithKline Plc, H. Lundbeck A/S, Mylan Inc., Neurocrine Biosciences, Inc., Pfizer Inc., Ratiopharm, Sanofi-Aventis, Valeant Pharmaceuticals, Watson Laboratories, among others.

The research report titled ?Anxiety Disorders: A Global Strategic Business Report? announced by Global Industry Analysts Inc., provides a comprehensive review of the anxiety disorders therapeutics markets, current market trends, key growth drivers, leading drugs in the market, overview of pipeline drugs, recent product approvals/launches, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for anxiety disorders therapeutics market for the years 2009 through 2017 for the following geographic markets – US, Europe, Asia-Pacific, and Rest of World. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.

For more details about this comprehensive market research report, please visit ? http://www.strategyr.com/Anxiety_Disorders_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world?s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

E-mail: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/

# # #







Read More

Lucas Distribution Announces New Market Focus for Universal Refrigerator Lock

July 07, 2012     No comments


Atlanta, GA (PRWEB) May 30, 2012

Lucas Distribution, LLC, an Atlanta-based worldwide distributor of office products and equipment, announces they will focus on a new market for their Universal Refrigerator Lock.

Refrigerator locks are often used to secure prescription drugs in refrigerators in hospitals and nursing homes.

They are also used to lock refrigerators in dorm rooms, apartments, boats or to lock an appliance that is located in a common area or is accessible to the public, such as a boating marina.

Lucas Distribution has now identified that families who live with loved ones who are affected by Autism, Alzheimer’s Disease, and Prader-Willi Syndrome have a need for secure, easy-to-operate Refrigerator Locks that are also simple to install.

“People who are affected by the above mentioned conditions often have an intense craving for food,” said General Manager Dave Lucas. “Our Universal Refrigerator Lock can be installed on almost any refrigerator and allows controlled access to the contents inside.”

Locks from Lucas Distribution are installed using a high-strength adhesive, making installation fast and easy without requiring any tools. “Most other refrigerator locks on the market require the use of two hands to unlock and remove a padlock and then release a cable,” said General Manager Dave Lucas. “Users of our locks will recognize that the key advantage of our product over competitors’ is that they can unlock the lock and open their refrigerator with one hand while holding an armful of groceries in the other.”

Locks are available in Black or White and multiple locks can be keyed alike at no additional cost.

Lucas Distribution also offers the FFPTL Refrigerator Lock, a typical padlock-style lock that installs on all refrigerators or freezers using its high-strength adhesive. Other available products include printer paper tray locks to secure laser prescription paper, blank checks, or other types of paper; storage and file cabinet locks; laptop and notebook cable locks; USB Dongle Lockboxes and printer cabinets.

To order PTL Refrigerator Locks or any of the many office supplies and quality products from Lucas Distribution, visit their website today. Customers can create a free account or shop as a guest, but either way they can be assured that they will have a secure and pleasant shopping experience.

For more product information, visit http://www.papertraylock.com/.

About Lucas Distribution:

Lucas Distribution, LLC, is an Atlanta-based, worldwide distributor of office equipment and security hardware. Lucas Distribution is one of the largest distributors of paper tray locks in the world and one of the nation?s largest copier cabinet distributors for the Ricoh, Canon, and Toshiba product line. It is expert at locking printers, copiers, and other types of office equipment with more than 42 years of combined experience between its partners. Beyond supplying high quality products at attractive prices, Lucas Distribution offer unparalleled customer service to all.







Find More Alzheimers Press Releases

Read More
« Older posts
Powered by WordPress | Designed by: best suv | Thanks to toyota suv, infiniti suv and lexus suv